Homing and invasiveness of MLL/ENL leukemic cells is regulated by MEF2C

Blood

Volumn 114, Issue 12, 2009, Pages 2476-2488

  Schwieger, Maike ^a   Schüler, Andrea ^a   Forster, Martin ^a   Engelmann, Afra ^a   Arnold, Michael A ^b   Delwel, Ruud ^c   Valk, Peter J ^c   Löhler, Jürgen ^a   Slany, Robert K ^d   Olson, Eric N ^b   Stocking, Carol ^a  

^a LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; HYBRID PROTEIN; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; LIGAND; MATRIX METALLOPROTEINASE; MINICHROMOSOME MAINTENANCE PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; RECEPTOR; TRANSCRIPTION FACTOR; BAM11 PROTEIN, MOUSE; DNA BINDING PROTEIN; INTERFERON REGULATORY FACTOR; MEF2C PROTEIN, MOUSE; MYOGENIC FACTOR; ONCOPROTEIN; TUMOR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER PATIENT; CELL HOMING; CELL INVASION; CONTROLLED STUDY; GENE IDENTIFICATION; GENETIC CODE; GENETIC SCREENING; HUMAN; HUMAN CELL; IMAGE INTENSIFIER; IN VIVO STUDY; LEUKEMIA CELL; MOTOR DEVELOPMENT; MOUSE; MOUSE STRAIN; MUTAGENESIS; MYELOPROLIFERATIVE DISORDER; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROVIRUS; TUMOR CELL; UPREGULATION; ANIMAL; BONE MARROW TRANSPLANTATION; C57BL MOUSE; CANCER INVASION; CANCER STEM CELL; CELL MOTION; CELL PROLIFERATION; CELL TRANSFORMATION; CLONOGENIC ASSAY; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSDUCTION; GENETICS; MALE; METABOLISM; MOUSE MUTANT; MURINE LEUKEMIA VIRUS; MYELOMONOCYTIC LEUKEMIA; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLONY-FORMING UNITS ASSAY; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTERFERON REGULATORY FACTORS; LEUKEMIA VIRUS, MURINE; LEUKEMIA, MYELOMONOCYTIC, ACUTE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED NOD; MICE, SCID; MYELOID-LYMPHOID LEUKEMIA PROTEIN; MYOGENIC REGULATORY FACTORS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENE PROTEINS, FUSION; TRANSCRIPTION FACTORS; TRANSDUCTION, GENETIC;

EID: 70350495169     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-158196     Document Type: Article

References (60)

1. Passegue E, Weisman IL. Leukemic stem cells: where do they come from? Stem Cell Rev. 2005; 1(3):181-188. (Pubitemid 41737094)
2. Warner J, Wang J, Hope K, Jin L, Dick JE. Concepts of human leukemic development. Oncogene. 2004;23(10):7164-7177.
3. Krivtsov A, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature. 2006;441(7104):818-822. (Pubitemid 44258912)
4. Cozzio A, Passegué E, Ayton P, Karsunky H, Cleary M, Weissman I. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors. Genes Dev. 2003;17(24):3029-3035. (Pubitemid 38040767)
5. Wong P, Iwasaki M, Somervaille T, So C, Cleary ML. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential. Genes Dev. 2007;21(21):2762-2774. (Pubitemid 350070722)
6. Zeisig B, Milne T, Garcia-Cuellar M, et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol. 2004;24(2): 617-628. (Pubitemid 38057914)
7. Kumar A, Hudson W, Chen W, Nishiuchi R, Yao Q, Kesey J. Hoxa9 influences the phenotype but not the incidence of MLL-AF9 fusion gene leukemia. Blood. 2004;103(5):1823-1828. (Pubitemid 38268979)
8. Holtschke T, Lö hler J, Kanno Y, et al. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996;87(2):307-317. (Pubitemid 26359008)
9. Burchert A, Cai D, Hofbauer L, et al. Interferon consensus sequence binding protein (ICSBP; IRF8) antagonizes BCR/ABL and down-regulates bcl-2. Blood. 2004;103(9):3480-3489. (Pubitemid 38525681)
10. Schmidt M, Bies J, Tamura T, Ozato K, Wolff L. The interferon regulatory factor ICSBP/IRF-8 in combination with PU.1 up-regulates expression of tumor suppressor p15(Ink4b) in murine myeloid cells. Blood. 2004;103(11):4142-4149. (Pubitemid 38685355)
11. Zhu C, Saberwal G, Lu Y, Platanias L, Eklund E. The interferon consensus sequence-binding protein activates transcription of the gene encoding neurofibromin 1. J Biol Chem. 2004;279(49): 50874-50885. (Pubitemid 40017826)
12. Potthoff M, Olson E. MEF2: a central regulator of diverse developmental programs. Development. 2007;134(23):4131-4140.
13. Schüler A, Schwieger M, Engelmann A, et al. The MADS transcription factor Mef2c is a pivotal modulator of myeloid cell fate. Blood. 2008; 111(9):4532-4541.
14. Johnnidis JB, Harris MH, Wheeler RT, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008;451(7182):1125-1129.
15. Wilker PR, Kohyama M, Sandau MM, et al. Transcription factor Mef2c is required for B cell proliferation and survival after antigen receptor stimulation. Nat Immunol. 2008;9(6):603-612. (Pubitemid 351712631)
16. Khiem D, Cyster J, Schwarz J, Black B. A p38 MAPK-MEF2C pathway regulates B-cell proliferation. Proc Natl Acad Sci U S A. 2008;105(44): 17067-17072.
17. Gekas C, Rhodes K, Gereige L, et al. Mef2C is a lineage-restricted target of Scl/Tal1 and regulates megakaryopoiesis and B-cell homeostasis. Blood. 2009;113(15):3461-3471.
18. Arnold M, Kim Y, Czubryt M, et al. MEF2C transcription factor controls chondrocyte hypertrophy and bone development. Dev Cell. 2007;12(3): 377-389. (Pubitemid 46300066)
19. Lin Q, Schwarz J, Bucana C, Olson E. Control of mouse cardiac morphogenesis, myogenesis by transcription factor MEF2C. Science. 1997; 276(5317):1404-1407. (Pubitemid 27235406)
20. Kuhn R, Schwenk F, Aguet M, Rajewsky K. Inducible gene targeting in mice. Science. 1995; 269(5229):1427-1429.
21. Schwieger M, Lö hler J, Fischer M, Herwig U, Tenen D, Stocking C. A dominant-negative mutant of C/EBPα, associated with acute myeloid leukemias, inhibits differentiation of myeloid and erythroid progenitors of man but not mouse. Blood. 2004;103(7):2744-2752.
22. Rodenburg M, Fischer M, Engelmann A, et al. Importance of receptor usage, Fli1 activation, and mouse strain for the stem cell specificity of 10A1 murine leukemia virus leukemogenicity. J Virol. 2007;81(2):732-742. (Pubitemid 46067899)
23. Schmidt M, Hoffmann G, Wissler M, et al. Detection and direct genomic sequencing of multiple rare unknown flanking DNA in highly complex samples. Hum Gene Ther. 2001;12(7):743-749. (Pubitemid 32692340)
24. Schwieger M, Lö hler J, Friel J, Scheller M, Horak I, Stocking C. AML1-ETO inhibits maturation of multiple lymphohematopoietic lineages and induces myeloblast transformation in synergy with ICSBP deficiency. J Exp Med. 2002;196(9):1227-1240.
25. Zeisig B, Garcia-Cuellar M, Winkler T, Slany R. The oncoprotein MLL-ENL disturbs hematopoietic lineage determination and transforms a biphenotypic lymphoid/myeloid cell. Oncogene. 2003; 22(11):1629-1637. (Pubitemid 36408178)
26. Kitamura T, Koshino Y, Shibata F, et al. Retrovirus-mediated gene transfer and expression cloning: powerful tools in functional genomics. Exp Hematol. 2003;31(11):1007-1014. (Pubitemid 37329742)
27. Cammenga J, Niebuhr B, Horn S, et al. RUNX1 DNA-binding mutants, associated with minimally differentiated acute myeloid leukemia, disrupt myeloid differentiation. Cancer Res. 2007;67(2):537-545. (Pubitemid 46192190)
28. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J. 1997;16(14):4226-4237. (Pubitemid 27298175)
29. Lu J, McKinsey T, Zhang C, Olson E. Regulation of skeletal myogenesis by association of the MEF2 transcription factor with class II histone deacetylases. Mol Cell. 2000;6(2):233-244.
30. Valk P, Verhaak R, Beijen M, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med. 2004;350(16):1617-1628. (Pubitemid 38528701)
31. Oostendorp R, Ghaffari S, Eaves C. Kinetics of in vivo homing and recruitment into cycle of hematopoietic cells are organ-specific but CD44- independent. Bone Marrow Transplant. 2000; 26(5):559-566. (Pubitemid 30702313)
32. Li J, Shen H, Himmel KL, et al. Leukaemia disease genes: large-scale cloning and pathway predictions. Nat Genet. 1999;23(3):348-353. (Pubitemid 29526436)
33. Hess JL, Bittner CB, Zeisig DT, et al. c-Myb is an essential downstream target for homeobox-mediated transformation of hematopoietic cells. Blood. 2006;108(1):297-304.
34. Möhle R, Bautz F, Rafii S, Moore M, Brugger W, Kanz L. The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor- 1. Blood. 1998;91(12):4523-4530. (Pubitemid 28270300)
35. Broxmeyer H, Pelus L, Kim C, Hangoc G, Cooper S, Hromas R. Synergistic inhibition in vivo of bone marrow myeloid progenitors by myelosuppressive chemokines and chemokine-accelerated recovery of progenitors after treatment of mice with Ara-C. Exp Hematol. 2006;34(8):1069-1077. (Pubitemid 44080386)
36. Somerville R, Oblander S, Apte S. Matrix metalloproteinases: old dogs with new tricks. Genome Biol. 2003;4(6):216. (Pubitemid 36758193)
37. Turcotte K, Gauthier S, Tuite A, Mullick A, Malo D, Gros P. A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice. J Exp Med. 2005;201(6):881-890. (Pubitemid 40524458)
38. Du Y, Spence SE, Jenkins NA, Copeland NG. Cooperating cancer-gene identification through oncogenic-retrovirus-induced insertional mutagenesis. Blood. 2005;106(7):2498-2505. (Pubitemid 41510825)
39. Hara T, Schwieger M, Kazama R, et al. Acceleration of chronic myeloproliferation by enforced expression of Meis1 or Meis3 in Icsbp-deficient bone marrow cells. Oncogene. 2008;27(27): 3865-3869. (Pubitemid 351862054)
40. Mullighan C, Goorha S, Radtke I, et al. Genomewide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446(7137): 758-764. (Pubitemid 46582031)
41. Rosenbauer F, Koschmieder S, Steidl U, Tenen DG. Effect of transcription-factor concentrations on leukemic stem cells. Blood. 2005;106(5):1519-1524. (Pubitemid 41208560)
42. Scheller M, Foerster J, Heyworth C, et al. Altered development and cytokine responses of myeloid progenitors in the absence of transcription factor, interferon consensus sequence binding protein. Blood. 1999;94(11):3764-3771.
43. Tsujimura H, Nagamura-Inoue T, Tamura T, Ozato K. IFN consensus sequence binding protein/IFN regulatory factor-8 guides bone marrow progenitor cells toward the macrophage lineage. J Immunol. 2002;169(3):1261-1269. (Pubitemid 34809167)
44. Steidl U, Rosenbauer F, Verhaak RG, et al. Essential role of Jun family transcription factors in PU.1 knockdown-induced leukemic stem cells. Nat Genet. 2006;38(11):1269-1277. (Pubitemid 44646289)
45. Lapidot T, Dar A, Kollet O. How do stem cells find their way home? Blood. 2005;106(6):1901-1910. (Pubitemid 41291700)
46. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med. 2006;12(10): 1167-1174. (Pubitemid 44527352)
47. Krause D, Lazarides K, von Andrian U, Van Etten R. Requirement for CD44 in homing an engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med. 2006;12(10):1175-1180. (Pubitemid 44527353)
48. Busillo J, Benovic J. Regulation of CXCR4 signaling. Biochim Biophys Acta. 2006;1768(4):952-963.
49. Brühl H, Cohen C, Linder S, Kretzler M, Schlöndorff D, Mack M. Post-translational and cell typespecific regulation of CXCR4 expression by cytokines. Eur J Immunol. 2003;33(11):3028-3037. (Pubitemid 37428335)
50. Kim H, De La Luz Sierra M, Williams C, Gulino A, Tosato G. G-CSF down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood. 2006;108(3):812-820. (Pubitemid 44154612)
51. Issafras H, Angers S, Bulenger S, et al. Constitutive agonist-independent CCR5 oligomerization and antibody-mediated clustering occurring at physiological levels of receptors. J Biol Chem. 2002;277(38):34666-34673. (Pubitemid 35052354)
52. Wang J, Alvarez R, Roderiquez G, Guan E, Norcross M. Constitutive association of cell surface CCR5 and CXCR4 in the presence of CD4. J Cell Biochem. 2004;93(4):753-760. (Pubitemid 44264171)
53. Kulbe H, Levinson NR, Balkwill F, Wilson JL. The chemokine network in cancer: much more than directing cell movement. Int J Dev Biol. 2004; 48(5):489-496. (Pubitemid 39360399)
54. Cignetti A, Vallario A, Roato I, et al. The characterization of chemokine production and chemokine receptor expression reveals possible functional cross-talks in AML blasts with monocytic differentiation. Exp Hematol. 2003;31(6):495-503. (Pubitemid 36793956)
55. Yi F, Jaffe R, Prochownik E. The CCL6 chemokine is differentiatlly regulated by c-Myc and LMyc, and promotes tumorigenesis and metastasis. Cancer Res. 2003;63(11):2923-2932. (Pubitemid 36667165)
56. de Visser K, Eichten A, Coussens L. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006;6(1):24-37. (Pubitemid 43053650)
57. Stefanidakis M, Koivunen E. Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression. Blood. 2006; 108(5):1441-1450. (Pubitemid 44316107)
58. Chang S, Young B, Li S, Qi X, Richardson J, Olson E. Histone deacetylase 7 maintains vascular integrity be repressing matrix metalloproteinase 10. Cell. 2006;126(2):321-334. (Pubitemid 44092958)
59. McKinsey T, Zhang C, Olson E. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci. 2002;27(1):40-47. (Pubitemid 34131624)
60. Fazi F, Racanicchi S, Zardo G, et al. Epigenetic silencing of the myelopoiesis regulator microRNA- 223 by the AML1/ETO oncoprotein. Cancer Cell. 2007;12(5):457-466. (Pubitemid 350046404)